KFSH localizes CAR-T therapy manufacturing in Riyadh

King Faisal Specialist Hospital and Research Centre has shifted its CAR-T program from imported treatments to local manufacturing in Riyadh, cutting treatment time from up to 28 days to about 14 days and lowering costs sharply. The move supports Saudi Arabia’s biotechnology push and extends KFSH’s advanced therapy capacity as the hospital prepares to discuss the work at a healthcare summit in New York City.

Why it matters: - Local CAR-T manufacturing reduces the time between a clinical decision and treatment for patients with aggressive blood cancers. - The shift removes reliance on cross-border shipping for a personalized therapy that uses each patient’s own cells. - KFSH has also cut the per-patient cost from about SAR 1.3 million to roughly SAR 250,000. - The capability strengthens Saudi Arabia’s push to localize biotechnology and build advanced therapy capacity inside the Kingdom.

What happened: - King Faisal Specialist Hospital and Research Centre moved its CAR T-cell program from imported therapies to local production on its Riyadh campus. - KFSH has treated more than 200 patients since launching the program in 2020. - The hospital began manufacturing genetically modified T cells on site in 2024. - KFSH treated the Kingdom’s first patient with locally manufactured CAR-T cells in a Phase I clinical trial for refractory acute lymphoblastic leukemia.

The details: - CAR T-cell therapy starts by collecting immune cells from a patient’s blood, genetically modifying them to recognize cancer cells, and reinfusing them. - When cells were manufactured abroad, the process could take up to 28 days. - Local manufacturing has reduced that timeline to about 14 days at KFSH’s dedicated facility. - KFSH says the local process has maintained cell viability and quality standards. - The hospital’s new facility for genetic and cellular therapies spans more than 5,000 square meters. - The site includes 16 modular clean-room clusters designed to adapt as therapeutic technologies evolve. - The facility is intended to produce CAR T-cell and stem-cell therapies and meet a meaningful share of national demand for advanced therapies. - KFSH has set a target of scaling to 100 gene therapy treatments annually.

Between the lines: - The move turns CAR-T from a logistics-heavy import model into a more controllable hospital capability. - Domestic manufacturing lets KFSH plan capacity rather than buy each treatment case by case. - The institutional setup links patient selection, cell collection, manufacturing, quality control and specialist care in one place. - That integration lowers risk for critically ill patients whose cells would otherwise need to be shipped abroad and returned. - The work also positions KFSH as a national showcase for advanced therapy manufacturing.

What’s next: - KFSH will expand its genetic and cellular therapy program through the new Riyadh facility. - The hospital will discuss the capability at the C3 US NYC Davos of Healthcare™ Summit 2026 on Sept. 14 in New York City. - The broader effort supports Saudi Arabia’s National Biotechnology Strategy and its 2040 goal of becoming a global hub for life sciences innovation.

The bottom line: - KFSH has brought CAR-T manufacturing in-house, and the result is faster treatment, much lower cost and a platform for wider advanced therapy production in Saudi Arabia.